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Abstract 
Background and aims:  Soluble c-erbB-2 oncoprotein has been proven as a useful 
marker in the management of breast cancer patients but its value in diagnostics and 
follow-up of colorectal cancer patients remains controversial. The aim of this study 
was to evaluate the usefulness of serum c-erbB-2 monitoring in diagnostics and 
prediction of disease outcome in rectal cancer patients. Patients and methods: Serum 
samples from 88 patients with rectal adenocarcinoma before surgery and 41 healthy 
controls were tested for the presence of c-erbB-2 oncoprotein by ELISA and the 
patients were followed-up for at least 5 years after surgery. Results: Preoperative 
serum c-erbB-2 levels were significantly higher in Stage IV patients than in healthy 
controls (P < 0.001) and did not show correlation with preoperative CEA levels. 
Elevated preoperative serum c-erbB-2 levels showed relatively high specificity (88%) 
and low sensitivity (44%) in diagnosis of rectal cancer. Elevated preoperative 
oncoprotein levels were predictive neither for overall survival nor for development of 
local recurrence/distant metastases. Conclusion: Although preoperative serum c-erbB-
2 levels were significantly higher in rectal cancer patients than in healthy controls, the 
soluble c-erbB-2 does not seem to be useful in diagnosis of rectal cancer due to its low 
sensitivity. Preoperative serum levels of this oncoprotein were predictive neither for 
overall survival nor for local recurrence/distant metastases in rectal cancer patients.  
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Introduction 
The c-erbB-2 (HER-2/neu) oncoprotein is a 185-kD epidermal growth factor receptor-
like transmembrane glycoprotein with tyrosine kinase activity. The extracellular 
domain of c-erbB-2 can be shed from cancer cells in cultures overexpressing c-erbB-2 
[1]. The antigen was also found in the sera of patients with breast [2, 3], 
hepatocellular [4], gastric [5], and ovarian cancers [6]. Possible clinical significance 
of soluble c-erbB-2 has been so far more extensively studied only in breast cancer 
patients, where its levels were hypothesized to correlate with the disease stage [7], 
with response to hormone therapy [8] and chemotherapy [9], and predicts for 
shortened survival [7]. Data related to serum c-erbB-2 levels in patients with rectal 
cancer is, to our knowledge, limited to 6 reports [10, 11, 12, 13, 14, 15]. Two of these 
reports are based on a small number of patients [10, 11] and no one has been dealing 
particularly with rectal cancer patients. The aim of this study was to assess the 
association of preoperative serum c-erbB-2 levels with tumor stage, local recurrence, 
distant metastases, and overall survival of rectal cancer patients.  
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Subjects and methods 
Subjects 
Healthy controls.  Forty-one healthy volunteers, aged 25 -75 years (median 53) among 
them 20 females (49%) and 21 males (51%) served as blood donors for determination 
of soluble c-erbB-2.  
Patients. A cohort of 88 patients with primary rectal adenocarcinoma, aged 28 - 79 
years (median 60), among them 35 females (40%) and 53 males (60%) were included 
in this prospective study. Preoperative diagnosis was established by standard 
diagnostic procedures, i.e. endoscopy and radiography, and when required by 
ultrasonography and computerized tomography.  Regarding tumor localization, all 
patients had rectal cancer; colon, cecal and anal cancers were not included in the 
study. All primary tumors were resected and pathohistologically confirmed to be 
adenocarcinomas. Tumor staging was carried out by AJCC Cancer Staging system 
[16]. There were 9 (10%) stage 0 patients, 24 (27%) stage I patients, 17 (19%) stage II 
patients, 20 (23%) stage III patients, and 18 (21%) stage IV  patients (13 with liver, 1 
with pulmonary, 1 with brain, 2 with bone, and 1 with peritoneal metastases). In the 
first year following surgery, the patients were followed-up according to a standardized 
protocol that included laboratory tests (routine blood cell count, CEA), 
ultrasonography of abdomen, computerized tomography of the pelvis, chest 
radiography and rectoscopy at 3-month intervals in the first year, at 6-months intervals 
in the second year after surgery and at yearly intervals afterwards. The study was 
carried out in compliance with the Helsinki Declaration II [17] and informed consent 
was obtained from all patients and healthy controls prior to their enrollment in the 
study.  
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Methods 
Serum c-erbB-2 determination. Blood samples were drawn by venepuncture 1-3 days 
before surgery between 7:00 and 8:00 a.m. and centrifuged. Sera were separated and 
stored in aliquots at -20o C until assayed. Levels of soluble c-erbB-2 oncoprotein were 
determined by enzyme-linked immunosorbent assay (Quantitative ELISA Assay 
neu/c-erbB-2, Oncogene Research Products, Calbiochem, USA) using monoclonal 
antibody specific for human  p185 neu/c-erbB-2 as well as for its extracellular fragment 
p105 (Ab-3). Results were expressed in human neu units (HNU)/mL.  
Serum CEA determination. Serum CEA levels were determined in serum samples 
obtained and stored as described above. An immunoradiometric assay for the 
quantitative determination of carcinoembryonic antigen in human serum or plasma 
was used (ELSA2-CEA, Cat. # 38C17, CIS Bio International, France), with the level 
of 5 ng/mL as a cut-off value. 
Statistical analysis 
The results are presented as medians with corresponding interquartile ranges and were 
analyzed by Kruskal-Wallis and Mann-Whitney U post-hoc tests with correction for 
multiple testing. P values < 0.05 were considered statistically significant.  Differences 
between categories were analyzed by χ2 test. Correlation between c-erbB-2 and CEA 
levels was analyzed by the Fisher’s exact test and by calculation of Pearson 
correlation coefficient.  Survival rates were calculated by the Kaplan-Meier method 
and compared using the log-rank test, with p<0.05 being considered statistically 
significant. Predictive value of preoperative c-erbB-2 levels was tested by ROC 
analysis.  
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Results 
On the basis of measurements in healthy volunteers, the concentration of 51.5 
HNU/ml c-erbB-2 was used as a cut-off value by the ROC analysis. Specificity, 
sensitivity, accuracy, false positive/negative ratios, and positive/negative predictive 
values of soluble c-erbB-2 in diagnosis of rectal cancer are shown in Table 1. With 
88% specificity at the selected cut-point, the sensitivity was 44% (39 out of 88 
patients with elevated c-erbB-2 values) and was lower than the sensitivity of CEA 
(48%, 42 out of 88 patients with elevated preoperative CEA levels, Table 2) in 
diagnosis of rectal cancer. There was no significant correlation between preoperative 
serum c-erbB-2 and CEA levels (r = 0.33, P=0.086).  Preoperative serum levels of c-
erbB-2 were significantly higher in stage IV patients than in healthy controls while 
there were no significant differences between patients with other disease stages and 
healthy individuals (Table 2).  Taking the value of 51.5 HNU/mL c-erbB-2 as a cut-
point, significantly more positive findings were noted among stage IV than in stage 0 
patients; there were no significant  differences between stage I - III and stage 0 
patients  (Table 3). During 5-year follow-up  (mean follow-up time 63.4 months) 45 
out of 70 patients who were disease-free after primary tumor resection remained 
disease-free, 10 developed local recurrence and 15 developed distant metastases. 
There was no difference in preoperative serum c-erbB-2 levels between disease-free 
patients and those who developed local recurrence but in those who developed distant 
metastases preoperative serum c-erbB-2 levels were significantly higher than in those 
who were disease-free (Figure 1). The proportion of patients with preoperative 
elevated c-erbB-2 values (> 51.5 HNU/mL) was also significantly higher among 
patients who developed distant metastases in comparison with those who remained 
disease-free (Figure 1). Cut-off value of 51.5 HNU c-erbB-2/mL was also used for the 
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survival analysis. Patients with elevated preoperative oncoprotein levels showed 
slightly shorter but nonsignificant overall survival compared to those with normal 
oncoprotein levels (42.9  months, 95% CI = 34.5-51.3 vs. 45.0 months, 95% CI = 
38.9-51.1, respectively;  log rank test = 0.63; p = 0.426; Figure 2). ROC analysis of 
elevated preoperative oncoprotein predictive value gave AUC of 0.540 (95% CI = 
0,386-0.694) for local recurrence and AUC of 0.583 (95 % CI = 0.444-0.723) for 
distant metastases. 
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Discussion 
Preoperative serum c-erbB-2  
In this study, we detected significantly higher preoperative serum c-erbB-2 levels in 
stage IV rectal cancer patients before surgery than in healthy individuals indicating a 
possible role for c-erbB-2 in colorectal cancer progression, as already suggested in 
two recently published reports [14, 15]. Regarding the diagnostic value of c-erbB-2, 
its sensitivity was the same (44%) as reported by Polychronidis and coworkers (44%) 
[15] and higher than the one reported by Tsigris and coworkers (41%) [14]. The 
specificity found in our study was also almost the same as in Polychronidis’ study 
(88% vs. 89% respectively) [15]. However, it was lower than reported by Tsigris et al. 
(97%) [14], probably because the sensitivity in their study was lower than in ours 
(41% vs. 44%, respectively). Significantly more patients with elevated c-erbB-2 were 
detected among those with distant metastases than among those with localized 
disease. Since the sensitivity of serum c-erbB-2 in diagnosis of rectal cancer was 
lower than the sensitivity of CEA, and since there was no correlation between serum 
levels of these two markers, serum c-erbB-2 does not seem to be of any value in 
increasing the sensitivity of rectal cancer diagnosis.   
Preoperative serum c-erbB-2 and survival 
Although a tendency for shorter overall survival of patients with elevated preoperative 
serum c-erbB-2 levels when compared to those with normal levels was noted this 
difference was not significant (log rank test, p=0.426). Polychronidis et al [15] 
reported similar results in their series of 52 colorectal cancer patients and ascribed the 
lack of significance to too small number of patients. However, we also failed to 
demonstrate statistical significance although our cohort comprised 88 patients. On the 
other hand, Tsigris et al [14] demonstrated the correlation of elevated serum c-erbB-2 
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levels with overall survival in their series of 63 colorectal cancer patients. This 
difference could be explained by more restrictive cut-off value for c-erbB-2 levels and 
correspondingly higher sensitivity obtained in our and Polychronidis’ than in Tsigris’ 
study. In addition, our cohort was more homogeneous with respect to tumor 
localization, comprising only rectal cancer patients. We also did not find elevated 
preoperative serum c-erbB-2 levels to be predictive for neither local recurrence nor 
distant metastases. Chamberlain et al [13] also reported that elevated serum c-erbB-2 
concentrations were not predictive of disease outcome in their cohort of 88 colorectal 
cancer patients. However, they did not specify whether this applied to overall survival 
or to a disease recurrence. In conclusion, elevated serum c-erbB-2 levels showed high 
specificity and positive predictive value and low sensitivity and negative predictive 
value so that these levels do not seem to be useful as a tumor marker in rectal cancer 
diagnosis. They also do not seem to be useful predictors of neither overall survival nor 
local recurrence/distant metastases in rectal cancer patients. 
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Table 1  Diagnostic value of elevated serum c-erbB-2  and CEA levels in patients 
with rectal cancer 
 Serum c-erbB-2  
> 51.5 HNU/mL 
Serum CEA               
> 5 ng/mL 
Specificity 88% 88% 
Sensitivity 44% 48% 
Accuracy 58% 59% 
False positive ratio (FP) 12% 12% 
False negative ratio (FN) 56% 52% 
Positive predictive value (PV+) 89% 92% 
Negative predictive value (PV-) 42% 38% 
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Table 2. Soluble c-erbB-2 levels in healthy subjects and rectal cancer patients before 
surgery regarding the stage of disease  
 
Subjects Stage of 
disease 
Number of 
subjects 
c-erbB-2, 
HNU/mL 
Healthy controls  41 42 (32-47)* 
Rectal cancer patients 0 9 38 (31-53) 
 I 24 44 (35-74) 
 II 17 47 (37-63) 
 III 20 52 (37-72) 
 IV 18 55 (39-72)‡ 
 
* Median (interquartile range); ‡p <0.001 vs. Healthy controls (Kruskal-Wallis test 
with Mann-Whitney post-hoc corrected for multiple tests). 
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Table 3.  Number and proportions of rectal cancer patients with elevated preoperative 
serum c-erbB-2 levels regarding stage of disease 
 
c-erbB-2 >51.5 HNU/mL Stage of disease 
Number of 
patients 
Proportion 
of patients 
 
χ
2
 
 
P vs. Stage 0 
0 1/9 0   
I 6/20 30 0.40 NS 
II 8/18 44 1.67 NS 
III 9/17 53 2.76 NS 
IV 15/24 63 5.02 0.025 
Total 39/88 44   
NS = not significant (χ2 test). 
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Figure 1. Preoperative serum c-erbB-2 levels in rectal cancer patients who were 
disease-free after primary tumor resection in relation to disease status after 5-year 
follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C-erbB-2 values: significantly higher in Distant metastases vs. Disease free (P<0.016, 
Mann Whitney, uncorrected); number of patients with elevated (>51.5 HNU/mL)       
c-erB-2: significantly higher in Distant metastases vs. Disease free (P=0.011, 
χ
2
=6.49); dashed line: cut-off value; straight lines: medians.  
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Figure 2.  Kaplan-Meier survival curve showing no significant difference in survival 
rates between rectal cancer patients with elevated and those with normal preoperative 
serum c-erbB-2 levels 
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